Methods for identifying cancer risk
AssigneeThe Johns Hopkins University School of Medicine
InventorAndrew P. Feinberg
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and kits for identifying an increased risk of developing cancer in a subject. The methods include analyzing a first biological sample, such as a blood sample, from the subject for loss of imprinting of the IGF2 gene. According to the methods a loss of imprinting is indicative of an increased risk of developing cancer. The method can include analyzing genomic DNA from the sample for altered methylation of the IGF2 gene. The altered methylation for example includes hypomethylation of a differentially methylated region of IGF2, corresponding to SEQ ID NO:1 or a polymorphism thereof. The method can be performed on a subject having no apparent or suspected hyperproliferative disorder such as cancer.
Claims47
A method for identifying an increased risk of developing cancer in a subject, comprising analyzing a first biological sample from the subject for loss of imprinting of the IGF2 gene, wherein a loss of imprinting is indicative of an increased risk of developing cancer, thereby identifying an increased risk of developing cancer in the subject.
A method for prognosing cancer risk of a subject, the method comprising analyzing a first biological sample from the subject for altered methylation of a differentially methylated region of IGF2, wherein the first biological sample is a blood sample, and wherein altered methylation is indicative of an increased risk of developing cancer, thereby prognosing cancer risk of the subject.
A method for identifying predisposition to colorectal cancer of a subject, comprising identifying a loss of imprinting of the IGF2 gene in a biological sample from the subject and correlating the loss with a predisposition to colorectal cancer, wherein loss of imprinting is associated with an increased predisposition to colorectal cancer, thereby identifying predisposition to colorectal cancer of the subject.
A kit for determining a methylation status of a differentially methylated region (DMR) of IGF2 corresponding to SEQ ID NO:1 or a polymorphism thereof, comprising an oligonucleotide probe, primer, or primer pair, or combination thereof, capable of selectively hybridizing to the DMR with or without prior bisulfite treatment of the DMR.
Dependencies are inferred from the claim text.